Black box warning contraindicated comedications: Concordance among three major drug interaction screening programs

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 28-34

  Wang, Lorraine M ^a   Wong, Maple ^b   Lightwood, James M ^b   Cheng, Christine M ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Black box warning; Drug interaction; Drug interaction screening program

Indexed keywords

AMIKACIN; AMPHOTERICIN B; BACITRACIN; CISPLATIN; CYCLOSPORIN; DOFETILIDE; ETACRYNIC ACID; FLUDARABINE; FUROSEMIDE; GALLIUM NITRATE; GENTAMICIN; ITRACONAZOLE; KANAMYCIN; MANNITOL; NEOMYCIN; PAROMOMYCIN; PENTOSTATIN; PIMOZIDE; POLYMYXIN B; QUINIDINE; STREPTOMYCIN; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; CARDIOVASCULAR DISEASE; DATA BASE; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG LABELING; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SCORING SYSTEM;

DATABASES, FACTUAL; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; DRUG LABELING; DRUG PRESCRIPTIONS; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; MASS SCREENING; PHARMACEUTICAL PREPARATIONS;

EID: 74549139076     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M475     Document Type: Article

References (28)

1. Code of federal regulations, title 201, section 57. www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr = 201.57 (accessed 2009 Jun 10).
2. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20. DOI 10.1001/jama.287.17.2215
3. Valuck R, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007;164:1198-1205. DOI:10.1176/appi.ajp.2007.07010007
4. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164:884-91. DOI 10.1176/appi.ajp.164.6.884
5. Thompson CA. Hospital inspectors eye black-box warnings. Am J Health Syst Pharm 2008;65:890-4. DOI 10.2146/news080039
6. Smith WD, Hatton RC, Fann AL, Baz MA, Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother 2005;39:45-50. Epub 14 Dec 2004. DOI 10.1345/aph.1E331
7. Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy 2007;27:1651-8. DOI 10.1592/phco.27.12.1651
8. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:368-86. DOI 10.1002/pds.1193
9. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J 1998;53:403-11.
10. Black box warnings by FormWeb, provided by Formulary Productions. http://formularyproductions.com/blackbox (accessed 2009 May 28).
11. The Institute for Safe Medication Practices Medication Safety Tools and Resources. http://ismp.org/Tools/default.asp (accessed 2009 June 10).
12. FDA Center for Drug Evaluation and Research (CDER) Drugs@FDA. www.accessdata.fda.gov/scripts/cder/drugsatfda. (accessed 2009 Jul 1).
13. Center for Biologics Evaluation and Research (CBER) Vaccines, Blood and Biologics. www.fda.gov/BiologicsBloodVaccines/default.htm. (accessed 2009 Jul 5).
14. Library of Medicine Current Medication Information page. http://dailymed.nlm.nih.gov/dailymed (accessed 2009 Jun 25).
15. Rosenberg JM, Koumis T, Nathan JP, Cicero LA, McGuire H. Current status of pharmacist-operated drug information centers in the United States. Am J Health Syst Pharm 2004;61:2023-32.
16. Kupferberg N, Jones HL. Evaluation of five full-text drug databases by pharmacy students, faculty and librarians: do the groups agree? J Med Libr Assoc 2004;92:66-71.
17. Kruskall WH. Ordinal measures of association. J Am Statistical Assoc 1958;53:814-61. DOI 10.2307/2281954
18. Cortina JM. What is coefficient alpha? An examination of theory and applications. J Appl Psychol 1993;78:98-104. DOI 10.1037/0021-9010.78.1.98
19. Bland JM, Altman DG. Statistics notes: Cronbach's alpha. BMJ 1997;314:572.
20. STATA Data Analysis and Statistical Software version 9. STATA Corp LP. College Station, TX, 2003.
21. SAS Institute. SAS version 9. Cary, NC.
22. Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM 2007;100:691-7. DOI 10.1093/qjmed/hcm088
23. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004;61:380-5.
24. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007;63:709-14. DOI 10.1111/j.1365-2125.2006.02809.x
25. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004;44:136-41. DOI 10.1331/154434504773062582
26. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci 2008;30:367-74. DOI 10.1007/s11096-008-9191-x
27. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug- drug interactions. Curr Ther Res 2000;61:540-8. DOI 10.1016/S0011-393X(00)80036-3
28. Murphy S, Roberts R. Black box 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006;117:34-9. DOI 10.1016/j.jaci.2005.10.031